Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$81.60 USD

81.60
4,618,519

+0.23 (0.28%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Zacks.com featured highlights ServiceNow, Boston Scientific and Cooper

ServiceNow, Boston Scientific and Cooper have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Profitable S&P 500 Stocks With Room to Run: NOW, BSX, COO

ServiceNow (NOW), Boston Scientific (BSX) and The Cooper Companies (COO) have been selected as the top picks with a high net income ratio.

GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare

GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.

Boston Scientific (BSX), Silk Road Merger Delayed for Review

Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.

Alcon's (ALC) Market Share Gains, New Launches Aid Growth

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.

Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?

Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.

Walgreens (WBA) Partners With BARDA to Boost Clinical Research

Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.

Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now

Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.

Urmimala Biswas headshot

Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?

Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.

Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt

Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.

The Zacks Analyst Blog Highlights Amazon, Boston Scientific, Shopify and Cooper-Standard

Amazon, Boston Scientific, Shopify and Cooper-Standard are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Amazon, Boston Scientific & Shopify

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Boston Scientific Corporation (BSX) and Shopify Inc. (SHOP), as well as a micro-cap stock, Cooper-Standard Holdings Inc. (CPS).

Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.

Here's Why Investors Should Hold Acadia (ACHC) Stock for Now

Acadia Healthcare (ACHC) remains well-poised for growth on the back of the solid demand for behavioral healthcare services, continuous pursuit of expansion initiatives and a notable financial position.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.